Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02681705 : Radiation Therapy and Combination Chemotherapy for Medulloblastoma
PhasePhase 2
AgesMin: 3 Years Max: 12 Years
Inclusion Criteria:

1. Histologically confirmed posterior fossa medulloblastoma

2. No residual tumor greater than 1.5 cm^2 after resection by postoperative MRI No tumor
in the spinal or cerebral subarachnoid space by MRI No tumor in the subarachnoid space
by Cerebrospinal fluid (CSF) No failure to perform staging studies (spine MRI and CSF
cytology) preoperatively or postoperatively

3. Must begin radiotherapy on study within 28 days after surgery

Exclusion Criteria:

1. Prior radiotherapy and anti-tumor chemotherapy other than corticosteroids are not

2. Patients must begin radiotherapy on protocol within 28 days of completion of surgery.
Exceptions need to be approved by the Principal Investigator.

3. Patients with the following will not be eligible:

> 1.5cm3 residual tumor following resection as indicated by post-operative MRI. tumor in
spinal or cerebral subarachnoid space either by MRI of brain and spine tumor in
subarachnoid space by CSF cytology failure to perform staging studies (spine MRI, CSF
cytology) either pre- or post- operatively
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557